Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda constant 5 (IGLC5) is a human gene classified as a **pseudogene**, meaning it does not encode a functional protein[2][7][10]. It is part of the immunoglobulin lambda locus, where several functional and non-functional immunoglobulin constant region genes are arranged in tandem on human chromosome 22[4]. Unlike other immunoglobulin genes, IGLC5 is non-functional and not involved in immunoglobulin expression, immune response, or drug targeting. There is no evidence for its use as a therapeutic target, drug interaction, or disease biomarker[2][7][10]. **Key notes:** - IGLC5 is *not* a druggable target or a functional entity. - It is a noncoding pseudogene with no known biological, pathological, or pharmacological role in humans[2][4][7][10]. - Molecular and clinical information is lacking because of its non-functional (pseudogene) status. If you're seeking information on a functional immunoglobulin lambda constant gene, refer instead to IGLC1, IGLC2, or IGLC3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda constant 5 (pseudogene) (IGLC5).